Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?

Peter Wipfler; Andrea Harrer; Georg Pilz; Katrin Oppermann; S Afazel; Elisabeth Haschke-Becher; Johann Sellner; Eugen Trinka; Jörg Kraus

doi:10.1111/ane.12182

Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?

Peter Wipfler (First author), Andrea Harrer (First author), Georg Pilz (Co-author), Katrin Oppermann (Co-author), S Afazel, Elisabeth Haschke-Becher (Co-author), Johann Sellner (Co-author), Eugen Trinka (Co-author), Jörg Kraus^* (Last author)

^*Corresponding author for this work

Research output: Contribution to journal › Original Article (Journal) › peer-review

19 Citations (Web of Science)

Original language	English
Pages (from-to)	e12-e15
Journal	ACTA NEUROLOGICA SCANDINAVICA
Volume	129
Issue number	3
DOIs	https://doi.org/10.1111/ane.12182
Publication status	Published - 2014

Keywords

RELAPSING MULTIPLE-SCLEROSIS
FINGOLIMOD
INTERRUPTION
RISK

Access to Document

10.1111/ane.12182

Cite this

Wipfler, P., Harrer, A., Pilz, G., Oppermann, K., Afazel, S., Haschke-Becher, E., Sellner, J., Trinka, E., & Kraus, J. (2014). Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal? ACTA NEUROLOGICA SCANDINAVICA , 129(3), e12-e15. https://doi.org/10.1111/ane.12182

Wipfler, Peter ; Harrer, Andrea ; Pilz, Georg et al. / Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?. In: ACTA NEUROLOGICA SCANDINAVICA 2014 ; Vol. 129, No. 3. pp. e12-e15.

@article{99a6460d75e0400fbe25374ab3baa18b,

title = "Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?",

keywords = "RELAPSING MULTIPLE-SCLEROSIS, FINGOLIMOD, INTERRUPTION, RISK",

author = "Peter Wipfler and Andrea Harrer and Georg Pilz and Katrin Oppermann and S Afazel and Elisabeth Haschke-Becher and Johann Sellner and Eugen Trinka and J{\"o}rg Kraus",

note = "P. Wipﬂer1*, A. Harrer1*, G. Pilz1, K. Oppermann 1, S. Afazel 2, E. Haschke-Becher 2, J. Sellner 1,3, E. Trinka 1, J. Kraus 1 1 Department of Neurology, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria; 2 Central Laboratory, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria; 3 Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany",

year = "2014",

doi = "10.1111/ane.12182",

language = "English",

volume = "129",

pages = "e12--e15",

journal = "ACTA NEUROLOGICA SCANDINAVICA ",

issn = "0001-6314",

number = "3",

}

Wipfler, P , Harrer, A , Pilz, G, Oppermann, K, Afazel, S, Haschke-Becher, E, Sellner, J, Trinka, E & Kraus, J 2014, 'Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?', ACTA NEUROLOGICA SCANDINAVICA , vol. 129, no. 3, pp. e12-e15. https://doi.org/10.1111/ane.12182

Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal? / Wipfler, Peter (First author); Harrer, Andrea (First author); Pilz, Georg (Co-author) et al.
In: ACTA NEUROLOGICA SCANDINAVICA , Vol. 129, No. 3, 2014, p. e12-e15.

Research output: Contribution to journal › Original Article (Journal) › peer-review